Abstract
ALTHOUGH the anti-depressant drug imipramine (‘Tofranil’, Geigy) has received broad clinicalacceptance, its mode of action remains uncertain. Nevertheless, potentiation of catecholamine activity is a well-defined pharmacological effect1–3. The other major class of anti-depressant drugs, the monoamine oxidase (MAO) inhibitors, have been shown clearly to inhibit the enzyme and to elevate brain levels of monoamines4; but it is far from certain that their clinical effect is owing to this biochemical property.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
